Background: Since the beginning of the COVID-19 outbreak in December 2019, a substantial body of COVID-19 medical literature has been generated. As of June 2020, gaps and longitudinal trends in the COVID-19 medical literature remain unidentified, despite potential benefits for research prioritisation and policy setting in both the COVID-19 pandemic and future large-scale public health crises. Methods: In this paper, we searched PubMed and Embase for medical literature on COVID-19 between 1 January and 24 March 2020. We characterised the growth of the early COVID-19 medical literature using evidence maps and bibliometric analyses to elicit cross-sectional and longitudinal trends and systematically identify gaps. Results: The early COVID-19 medical literature originated primarily from Asia and focused mainly on clinical features and diagnosis of the disease. Many areas of potential research remain underexplored, such as mental health, the use of novel technologies and artificial intelligence, pathophysiology of COVID-19 within different body systems, and indirect effects of COVID-19 on the care of non-COVID-19 patients. Few articles involved research collaboration at the international level (24.7%). The median submission-to-publication duration was 8 days (interquartile range: 4-16). Conclusions: Although in its early phase, COVID-19 research has generated a large volume of publications. However, there are still knowledge gaps yet to be filled and areas for improvement for the global research community. Our analysis of early COVID-19 research may be valuable in informing research prioritisation and policy planning both in the current COVID-19 pandemic and similar global health crises.
Background This study aimed to evaluate the predictive value of long non‐coding RNA intersectin 1‐2 (lnc‐ITSN1‐2) for acute ischemic stroke (AIS) risk, and investigate its correlation with disease severity, inflammation, and recurrence‐free survival (RFS) in AIS patients. Methods Three hundred and twenty AIS patients were recruited, and plasma samples were collected within 24 hours after admission. lnc‐ITSN1‐2 expression form plasma was detected by reverse transcription‐quantitative polymerase chain reaction (RT‐qPCR). The National Institute of Health Stroke Scale (NIHSS) score was assessed, and RFS was calculated. Meanwhile, 320 controls were enrolled and plasma samples were collected on the enrollment, and lnc‐ITSN1‐2 expression was detected by RT‐qPCR. Results lnc‐ITSN1‐2 expression was increased in AIS patients compared to controls (P < .001), and receiver operating characteristic curve revealed its predictive value for AIS risk (area under the curve: 0.804, 95% confidence interval, 0.763‐0.845). In AIS patients, lnc‐ITSN1‐2 expression was positively correlated with NIHSS score (r = 0.464, P < .001). For inflammation, lnc‐ITSN1‐2 expression was positively correlated with CRP (r = 0.398, P < .001), TNF‐α (r = 0.502, P < .001), IL‐1β (r = 0.313, P < .001), IL‐6 (r = 0.207, P < .001), IL‐8 (r = 0.400, P < .001), IL‐17 (r = 0.272, P < .001), and IL‐22 (r = 0.222, P < .001). In terms of predicted target microRNAs, lnc‐ITSN1‐2 expression was negatively correlated with microRNA (miR)‐107 (r = −0.467, P < .001), miR‐125a (r = −0.494, P < .001), and miR‐146a (r = −0.126, P = .025). For prognosis, high lnc‐ITSN1‐2 expression was correlated with worse RFS in AIS patients. Conclusion lnc‐ITSN1‐2 exerts a good predictive value for AIS risk; meanwhile, its increased expression is correlated with enhanced disease severity, elevated inflammation, and worse RFS in AIS patients.
The aim of this prospective, double-blinded pilot trial study was to evaluate the effects of Thymosin alpha 1 use in the early phase on immunomodulation and clinical outcomes in patients with severe acute pancreatitis (SAP). A total of 24 patients with SAP were randomized to receive either conventional therapy for SAP or immunomodulatory therapy (TA1 group). The patients in the thymosin group were injected with Talpha1 3.2 mg twice per day for 7 days. The serum level of HLA-DR and CD4/CD8 ratio and other immune parameters were measured on admission, the 8th day and the 28th day. There was a low expression of monocyte HLA-DR in both groups on admission, and more rapid alterations in the HLA-DR were found in the TA1 group. The positive rates of blood and abdominal drainage culture were statistically significant during the 28th follow-up period. The duration of ICU stay was shorter after TA1 treatment. Improves cell-induced immunity and reduces infection rate in severe acute pancreatitis patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.